Working… Menu

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04110093
Recruitment Status : Recruiting
First Posted : October 1, 2019
Last Update Posted : December 30, 2020
Information provided by (Responsible Party):
Yuan-Sheng Zang, Shanghai Changzheng Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 31, 2021
Estimated Study Completion Date : August 31, 2021